An Expert Overview of Immunotherapy for Advanced HCC

Link to CME: Claim Credit

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:

• Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumab
• Use of nivolumab ± ipilimumab and pembrolizumab
• Emerging immunotherapy combinations currently being investigated in clinical trials
• Management of key adverse events with immune checkpoint inhibitors

Presenters:
Amit G. Singal, MD, MS
Chief of Hepatology
Medical Director, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Lipika Goyal, MD
Lead of the Liver Cancer Research Program
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.

Link to full program:
http://bit.ly/39V6s72

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.